Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Circulation · 04.03.2025 · 151 (9) · 601-611
DOI: 10.1161/circulationaha.124.072771 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 04.03.2025. Verfasst von Daniel P Judge und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Medical University of South Carolina, Charleston (D.P.J.). Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, BridgeBio Inc..
Abstract (Originalsprache)
BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE. METHODS: Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42. RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46–0.72) at month 42 based on a stratified Cox proportional hazards model ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Medical University of South Carolina, Charleston (D.P.J.).
- National Amyloidosis Centre, University College London, Royal Free Hospital, UK (J.D.G., M.F.).
- Division of Cardiovascular Medicine, Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Palo Alto, CA (K.M.A.).
- Department of Medicine, Division of Cardiology, Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (A.V.A.).
- Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, IT (F.C.).
- Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda and Centro Nacional de Investigaciones Cardiovasculares, Madrid, ES (P.G.-P.).
ORCID-Profile: Daniel P Judge, Julian D Gillmore, Kevin M Alexander, Amrut V Ambardekar, Francesco Cappelli, Marianna Fontana, Pablo García-Pavía, Justin L Grodin, Martha Grogan, Ahmad Masri, Jose Nativi-Nicolau, Laura Obici, Nitasha Sarswat, Prem Soman, Ted Lystig, Jonathan C Fox, Mathew S Maurer
Förderung
- NHLBI NIH HHS
- BridgeBio Inc.
Zitieren
APA
Judge, D. P., Gillmore, J. D., Alexander, K. M., Ambardekar, A. V., Cappelli, F., Fontana, M., García-Pavía, P., Grodin, J. L., Grogan, M., Hanna, M., Masri, A., Nativi-Nicolau, J., Obici, L., Hvitfeldt Poulsen, S., Sarswat, N., Shah, K., Soman, P., Lystig, T., Cao, X., …, & Maurer, M. S. (2025). Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation, 151(9), 601-611. https://doi.org/10.1161/circulationaha.124.072771
Vancouver
Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, et al. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025;151(9):601-611. doi:10.1161/circulationaha.124.072771
BibTeX
@article{Judge2025,
author = {Judge, Daniel P and Gillmore, Julian D and Alexander, Kevin M and Ambardekar, Amrut V and Cappelli, Francesco and Fontana, Marianna and García-Pavía, Pablo and Grodin, Justin L and Grogan, Martha and Hanna, Mazen and Masri, Ahmad and Nativi-Nicolau, Jose and Obici, Laura and Hvitfeldt Poulsen, Steen and Sarswat, Nitasha and Shah, Keyur and Soman, Prem and Lystig, Ted and Cao, Xiaofan and Wang, Kevin and Pecoraro, Maria Lucia and Tamby, Jean-François and Katz, Leonid and Sinha, Uma and Fox, Jonathan C and Maurer, Mathew S},
title = {Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial},
journal = {Circulation},
year = {2025},
volume = {151},
number = {9},
pages = {601--611},
doi = {10.1161/circulationaha.124.072771}
}
EUVIMED